Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders

Tunç, Serhat; Atagün, Murat İlhan; Neşeli̇oğlu, Salim; Bilgin, Yelda Yenilmez; Başbuğ, Hamit Serdar; Erel, Özcan

doi:10.1080/24750573.2018.1517466

Cited by 13 publications

(6 citation statements)

References 45 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IMA's diagnostic value in psychiatric disorders, such as AD, schizophrenia, and bipolar disorders, is controversial [101,102]. An increase in IMA, IMAR, and some markers for oxidative stress, such as advanced oxidation protein products (AOPP), ceruloplasmin, and prooxidant-antioxidant balance (PAB), has been shown in AD, the most common form of dementia in the elderly population [99,119].…”

Section: Neurological Disordersmentioning

confidence: 99%

Ischemia-Modified Albumin: Origins and Clinical Implications

et al. 2021

View full text Add to dashboard Cite

Albumin is one of the most abundant proteins in the body of mammals: about 40% of its pool is located in the intravascular space and the remainder is found in the interstitial space. The content of this multifunctional protein in blood is about 60-65% of total plasma proteins. A decrease in its synthesis or changes of functional activity can destabilize oncotic blood pressure, cause a violation of transporting hormones, fatty acids, metals, and drugs. Albumin properties change under ischemic attacks associated with oxidative stress, production of reactive oxygen species, and acidosis. Under these conditions, ischemia-modified albumin (IMA) is generated that has a reduced metal-binding capacity, especially for transition metals, such as copper, nickel, and cobalt. The method of determining the cobalt-binding capability of HSA was initially proposed to evaluate IMA level and then licensed as an ACB test for routine clinical analysis for myocardial ischemia. Subsequent studies have shown the viability of the ACB test in diagnosing other diseases associated with the development of oxidative stress. This review examines recent data on IMA generation mechanisms, describes principles, advantages, and limitations of methods for evaluation of IMA levels, and provides detailed analysis of its use in diagnostic and monitoring therapeutic efficacy in different diseases.

show abstract

Section: Neurological Disordersmentioning

confidence: 99%

Ischemia-Modified Albumin: Origins and Clinical Implications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In a study, no significant difference was found in serum IMA levels in bipolar disorder patients during the remission period when compared with the control group [22]. However, another study showed increased IMA levels in bipolar disorder patients during the remission period as compared to the control group, but no significant difference was found in unipolar depression patients [23]. Data from a limited number of studies evaluating IMA levels in psychiatric disorders differ.…”

Section: Discussionmentioning

confidence: 92%

Evaluation of ischemia modified albumin levels in major depression patients

Karaaslan¹,

Hacımusalar²,

Amuk³

et al. 2019

Journal of Surgery and Medicine

View full text Add to dashboard Cite

Aim: Depression is an important public health problem, which has been associated with an antioxidant defense system. Ischemia-modified albumin (IMA) is a new biomarker that measures ischemia. The aim of this study was to evaluate IMA levels as a new parameter related to oxidative stress in patients with major depressive disorder (MDD). Methods: This cross-sectional case-control study included 59 patients aged between 18-65 years who were admitted to our psychiatry outpatient clinic between June 2018 and December 2018, diagnosed with MDD and had not used psychotropic drugs for 3 months. In addition, 59 age and sex matched healthy controls were included in the study. Serum IMA and albumin levels were measured in blood samples taken from each patient and from control groups. Hamilton Depression Rating Scale (HDRS) was applied to the subjects to evaluate the depression level. Results: Among the MDD group, 27 patients (45.8%) were male and 32 (54.2%) were female. The number of males and females in the control group were 29 (49%) and 30 (51%). Mean ages of the patients in MDD and control groups were 39.40 (12.20) and 38.67 (9.29) years, respectively. No statistically significant difference was found between the groups in terms of age and gender (P=0.942 and P=0.714, respectively). The mean IMA level of MDD and control group patients were 0.84 (0.39) and 0.82 (0.30), respectively; the difference was statistically significant (P<0.001). There was also a statistically significant difference between the albumin levels of the two groups (P=0.01). Correlation analysis showed a positive correlation between serum IMA levels and HDRS scores (r=0.235, P=0.008). Conclusion: In our study, IMA levels of MDD patients were significantly higher than that of the control group. This result may be an indicator of increased oxidative stress in patients with depression. There is little data in the literature evaluating IMA levels in psychiatric disorders.

show abstract

“…CRP is an APR that rapidly reacts to inflammatory processes as well as the major protein carrier for serum Cu [51][52][53]. Most psychiatric disorders, especially SZ and BD are related to an inflammatory reaction by the activation of the glia in the neural tissue [54,55]. On the other hand, obesity/overweight is associated with increased inflammation in SZ and BD patients [56,57].…”

Section: Discussionmentioning

confidence: 99%

Serum ceruloplasmin-ferroxidase activity in bipolar disorder is elevated compared to major depressive disorder and schizophrenia: a controlled study

Tunç

Atagün

Başbuğ

et al. 2019

Psychiatry and Clinical Psychopharmacology

Self Cite

View full text Add to dashboard Cite

OBJECTIVE: In this study, we aimed to study copper metabolism in schizophrenia, bipolar disorder, major depression compared with healthy control. METHODS: This is a single-centered cross-sectional study. The patients with schizophrenia (n = 36), bipolar disorder (n = 37), major depression (n = 40), and healthy control (n = 32) were included in the study. All participants were initially evaluated by a clinical psychiatrist to confirm the appropriate diagnosis using the Structured Clinical Interview for Diagnostic and Statistical Manuel of Mental Disorders-IV (DSM-IV) Axis I Disorders (SCID-I). Serum copper level, ceruloplasmin mass, and ceruloplasmin-ferroxidase activity were measured. One-way ANOVA and Kruskal-Wallis Tests were performed for statistical analyses. RESULTS: Serum ceruloplasmin-ferroxidase activity (χ 2 = 9.11, p = 0.028) demonstrated a significant statistical difference in all groups compared with the control group. Serum ceruloplasmin-ferroxidase activity of the bipolar disorder group was significantly higher than the healthy control group (p = 0.012), major depression group (p = 0.027), and the schizophrenia group (p = 0.019). Erythrocyte sedimentation rate (ESR) (p = 0.028) and waist circumference (p = 0.005) in bipolar disorder group, and the C-reactive protein (CRP) (p < 0.001) and cholesterol (p = 0.043) in the schizophrenia group were found as the determinants of ceruloplasmin-ferroxidase activity. CONCLUSION: In this study, ceruloplasmin-ferroxidase activity is higher in all groups in comparison to the healthy control. The significantly higher ceruloplasmin-ferroxidase activity was shown in bipolar disorder followed by the major depression and schizophrenia. The ceruloplasmin-ferroxidase activity was correlated with erythrocyte sedimentation rate in the bipolar disorder group and with C-reactive protein in the schizophrenia group. Therefore, the ceruloplasmin-ferroxidase activity may be an encouraging candidate in the neuro-immune modulation and become a reliable clinical tool for demonstrating the strong association of inflammation in these disorders.

show abstract

Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders

Cited by 13 publications

References 45 publications

Ischemia-Modified Albumin: Origins and Clinical Implications

Ischemia-Modified Albumin: Origins and Clinical Implications

Evaluation of ischemia modified albumin levels in major depression patients

Serum ceruloplasmin-ferroxidase activity in bipolar disorder is elevated compared to major depressive disorder and schizophrenia: a controlled study

Contact Info

Product

Resources

About